EN DE
STOCK COMPARISON

Excelsior Medical Co vs McKesson: Fair Value & Quality

Both stocks run through our valuation models. Here is how Excelsior Medical Co (4104) and McKesson (MCK) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Excelsior Medical Co trades at TWD 71.20 versus a fair value of TWD 53.49 (-25%), while McKesson trades at $870 versus $819 (-6%).
Excelsior Medical Co
4104.TW · TWD · Health Care
-25%
upside to fair value
overvalued
PriceTWD 71.20
Fair ValueTWD 53.49
Quality39/100
McKesson
MCK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$870
Fair Value$819
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Excelsior Medical CoMcKesson
Valuation
15.5×P/E (TTM)21.0×
1.50×P/S (TTM)0.23×
1.47×P/B
11.9×EV/EBITDA13.9×
PEG1.57×
6.0%Dividend yield0.4%
TWD 4.30Dividend per share$3.17
Profitability
9%Net margin1%
8%Operating margin2%
8%Return on equity
2%Return on assets5%
Growth
9%Revenue growth (YoY)6%
6.9%Avg. growth/yr (3Y)13.4%
5.7%Avg. growth/yr (5Y)11.1%
Balance & size
0.04×Debt / equity
$419MMarket cap$94B
expensiveGrowth qualityhealthy

Excelsior Medical Co leads: 6 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Excelsior Medical Coof which business quality 38 · market factors 48 McKessonof which business quality 65 · market factors 63
ProfitabilityMargins and returns on capital today
34
49
Quality GrowthAre margins and returns improving?
48
65
CashflowEarnings quality: real cash, not paper profit
0
47
Fin. StrengthBalance sheet, leverage, solvency risk
75
72
InvestmentDisciplined investing over empire-building
86
76
Low VolatilityCalm price path (market factor)
100
83
MomentumPrice trend over the last 3–12 months (market factor)
30
51
52W MomentumDistance to the 52-week high (market factor)
18
62
Net IssuanceBuybacks instead of dilution
0
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Excelsior Medical Co

DCF ModelsTWD 108
Earnings-BasedTWD 35.44
Dividend DiscountTWD 56.16
MultiplesTWD 76.38
Asset-BasedTWD 32.70
Economic ProfitTWD 44.85
Growth EarningsTWD 82.14

9 of 17 models see the stock below the current price.

McKesson

DCF Models$955
Earnings-Based$444
Dividend Discount$57.26
Multiples$848
Growth DCF$922
Economic Profit$497
Growth Earnings$708

13 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Excelsior Medical Co
Bear TWD 35.60Fair Value TWD 53.49Bull TWD 77.27
TWD 71.20 = current price (white tick)
McKesson
Bear $605Fair Value $819Bull $1,034
$870 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Excelsior Medical Co · Health Care

Quality score39 · bottom 25%
Fair value upside-25% · above median

McKesson · Health Care

Quality score66 · Top 25%
Fair value upside-6% · above median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Excelsior Medical Co trades at TWD 71.20 versus a fair value of TWD 53.49 (-25%), while McKesson trades at $870 versus $819 (-6%).

McKesson has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.